artrose-hofte
Portal
/
Laegehaandbogen
/
ortopaedi
/
tilstande-og-sygdomme
/
baekken-hofte-og-laar
/
artrose-hofte
/
Home
Data
patienthaandbogen
Sundheddk apps
Laegehaandbogen
Klinikpersonale
akut-og-foerstehjaelp
allergi
arbejdsmedicin
blod
brystsygdomme
boern-og-unge
boerne-og-ungdomspsykiatri
endokrinologi
forsikringsmedicin
fysmed-og-rehab
generelt
geriatri
gynaekologi
hjerte-kar
hud
infektioner
kirurgi
kraeft
lunger
mandlige-koensorganer
mave-tarm
neurologi
nyrer-og-urinveje
obstetrik
ortopaedi
symptomer-og-tegn
tilstande-og-sygdomme
haandled-og-haand
albue-og-underarm
skulder-og-overarm
nakke-ryg-og-bryst
baekken-hofte-og-laar
hamstringsskade
mb-calv-legg-perthes
hofteledsdysplasi
seroes-coxitis
quadricepsskader
artrose-hofte
piriformissyndromet
epifysiolysis-capitis-femoris
hofteimpingement
femoral-anteversion
femoral-retroversion
hofteledsluksation
lyskeskade-i-laarets-indadfoerende-muskler
knae
laeg-ankel-og-fod
knoglebrud
oevrige-sygdomme
behandlinger
undersoegelser
patientinformation
illustrationer
psykiatri
paediatri
rejsemedicin-vacciner
reumatologi
sexsygdomme
sjaeldne-sygdomme
socialmedicin
oeje
oere-naese-hals
sundhedsoplysning
undersoegelser-og-proever
om-laegehaandbogen
soeg
dli-medicin
Apps
Brugermanual
<Provider Id="sundheddkcms"> <Item Id="{459F747F-3A1F-4339-B887-DA7BB7A3FC2F}" Name="artrose-hofte" Type="LHContentPage" ParentProviderId="sundheddkcms" ParentItemId="{F8682618-AC08-4F28-A8EC-26343008934E}" SortOrder="500" PublishDate="2009-02-05T08:42:00" DeleteDate="2999-12-31T00:00:00" PotItemType=""> <Content> <HtmlField Name="PageContent"><![CDATA[<h2>Diagnose</h2> <h3>Diagnostiske kriterier</h3> <ul> <li>Diagnosen stilles ud fra klinikken og støttet af røntgenfund</li> <li>Der er ikke altid sammenhæng mellem klinik og røntgenfund, i så fald er klinikken afgørende</li> </ul> <h3>Sygehistorie</h3> <ul> <li>Gradvis udvikling af smerter lokaliseret i lysken fortil og nogle gange lateralt på låret, ofte strålende ned mod knæet. Knæsmerter kan være eneste tegn på artrose i hoften</li> <li>Smerterne er ofte relateret til aktivitet, og generne øges ved meget aktivitet og mindskes ved mindre aktivitet</li> <li>Typisk er der igangssætnings-smerter, som forsvinder efter nogen tid, men som kommer tilbage efter nogen tids belastning</li> <li>Hvile- og nattesmerter udvikles gradvist. Ved nattesmerter er tilstanden fremskreden</li> <li>Gangfunktionen påvirkes med nedsat distance, behov for stok (bruges på modsat side) og halten</li> </ul> <h3>Kliniske fund</h3> <ul> <li>Inspektion <ul> <li>Atrofi af gluteal- og lårmuskulatur ses ofte</li> </ul> </li> <li>Bevægeligheden <ul> <li>Er afficeret i tidlige stadier og har høj prædiktionsværdi for artrose</li> <li>Tidlige tegn på hofteledsartrose er smerte og indskrænket passiv bevægelighed </li> </ul> </li> <li>Kontrakturer <ul> <li>Kan opstå, som oftest i flekteret, adduceret og udadroteret stilling</li> <li>Kontrakturer kan give en funktionel anisomeli med sekundær skoliose</li> </ul> </li> <li>Hos 20 % er tilstanden bilateral, begge hofter bør derfor undersøges<a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD19201242559&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H19201243076&us=sitecore%5Canvi&mo&pe=0&fbd=1" data-type="journal-reference" data-value="Lane NE, Osteoarthritis of the hip. N Engl J Med 2007;357: 1413-21" data-value-piped="Lane NE|Osteoarthritis of the hip|N Engl J Med|2007|357|1413-21" data-url="reference-link" title="Lane NE, Osteoarthritis of the hip. N Engl J Med 2007;357: 1413-21"><sup>1</sup></a></li> </ul> <h3>Supplerende undersøgelser i almen praksis</h3> <ul> <li>Blodprøver <ul> <li>Kan evt. tages for at udelukke andre sygdomme såsom infektion, men er ellers ikke indiceret</li> </ul> </li> </ul> <h3>Andre undersøgelser hos specialist</h3> <ul> <li>Røntgen <ul> <li>Røntgenforandringer optræder sent i artrosesygdommens forløb</li> <li>Viser karakteristisk ledspalteforsnævring, osteofytter, subkondral sklerose og cystedannelse </li> </ul> </li> </ul> <h3>Differentialdiagnoser</h3> <ul> <li><a href="~/link.aspx?_id=33B41768A4164413B268ED5E1FB26938&_z=z">Trochantertendinitis</a> (bursitis)</li> <li><a href="~/link.aspx?_id=BA77007FD5454D78BF5B5701D82C0135&_z=z">Ischias</a></li> <li><a href="~/link.aspx?_id=B6A02B03C1E84B028FF1E4B58AB490AF&_z=z">Piriformissyndrom</a></li> <li>Neoplasme - metastaser</li> <li>Inflammationer i gluteus medius eller tensor fascia lata</li> </ul> <h2>Behandling</h2> <h3>Behandlingsmål</h3> <ul> <li>Kontrollere smerter og andre gener</li> <li>Bevare og evt. forbedre funktionsniveau</li> </ul> <h3>Generelt om behandlingen</h3> <ul> <li>En helhedsvurdering må altid foretages og valg af behandling må vurderes i forhold til patientens generelle helbredstilstand. Dette er ofte ældre mennesker med supplerende gener</li> <li>Initielt behandles med svage analgetika og muskelstyrkende træning af muskler omkring hoften. Endvidere vægtreduktion ved behov</li> <li>Standardbehandlingen ved invaliderende artrose hos patienter over 50 år er indsættelse af hofteprotese</li> </ul> <h3>Håndtering i almen praksis</h3> <ul> <li>Igangsætning af træning</li> <li>Vægttab ved behov</li> <li>Medicinsk smertebehandling med svage analgetika</li> <li>Henvisning til røntgen undersøgelse af hofteled</li> <li>Ved manglende effekt af initial behandling, da henvisning til ortopædkirurgisk afdeling</li> </ul> <h3>Råd til patienten</h3> <ul> <li>Vægtreduktion<a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD19201242559&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H19201243340&us=sitecore%5Canvi&mo&pe=0&fbd=1" data-type="journal-reference" data-value="Lievense AM, Bierma-Zeinstra SM, Verhagen PA, van Baar ME, Verhaar JS, Koes BW, Influence of obesity on the development of osteoarthritis of the hip: a systematic review. Rheumatology (Oxford) 2002;41: 1155-62" data-value-piped="Lievense AM, Bierma-Zeinstra SM, Verhagen PA, van Baar ME, Verhaar JS, Koes BW|Influence of obesity on the development of osteoarthritis of the hip: a systematic review|Rheumatology (Oxford)|2002|41|1155-62" data-url="reference-link" title="Lievense AM, Bierma-Zeinstra SM, Verhagen PA, van Baar ME, Verhaar JS, Koes BW, Influence of obesity on the development of osteoarthritis of the hip: a systematic review. Rheumatology (Oxford) 2002;41: 1155-62"><sup>2</sup></a>. Dette er ikke mindst vigtigt forud for en operation med indsættelse af protese</li> <li>Undgå langvarigt og stående arbejde, tunge og længerevarende løft</li> <li>Fordel at ligge på maven eller på siden med pude mellem benene for at undgå kontrakturer, når man sover</li> <li>Fysisk aktivitet i form af cykling eller svømning<a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD19201242559&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H19201243340&us=sitecore%5Canvi&mo&pe=0&fbd=1" data-type="journal-reference" data-value="Hinman RS, Heywood SE, Day AR, Aquatic physical therapy for hip and knee osteoarthritis: results of a single-blinded randomized controlled trial. Phys Ther 2007;87: 32-43" data-value-piped="Hinman RS, Heywood SE, Day AR|Aquatic physical therapy for hip and knee osteoarthritis: results of a single-blinded randomized controlled trial|Phys Ther|2007|87|32-43" data-url="reference-link" title="Hinman RS, Heywood SE, Day AR, Aquatic physical therapy for hip and knee osteoarthritis: results of a single-blinded randomized controlled trial. Phys Ther 2007;87: 32-43"><sup>3</sup></a> anbefales</li> <li>Benytte krykke/stok kontralateralt for den smertende hofte</li> </ul> <h3>Medicinsk behandling</h3> <h4>Behandlingsstrategier</h4> <ul> <li>Dosering <ul> <li>Behandling kan gives ved behov, intermitterende eller kontinuerlig</li> <li>Hos patienter med lette og moderate gener vil behandling ved behov være tilstrækkelig. Det kan være aktuelt at give højere initialdose end de doser, som bruges ved kontinuerlig behandling </li> </ul> </li> <li>Kombinationsbehandling <ul> <li>Til smertelindring anvendes [DliActiveSubstance;6381;paracetamol] i rekommanderede doser</li> <li>Kombination af lægemidler med forskellige virkningsmekanismer (fx [DliActiveSubstance;6381;paracetamol] og <a href="http://pro.medicin.dk/Laegemiddelgrupper/Grupper/213010">NSAID</a>) kan være nyttig hos nogle patienter. NSAID bør ikke anvendes som længerevarende behandling, men kan anvendes behovsrelateret</li> <li>Morfika bør ikke anvendes<a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD15369374474&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H15369374529&us=sitecore%5Csoko&mo&pe=0&fbd=1" data-type="journal-reference" data-value="da Costa BR, Nüesch E, Kasteler R, Husni E, Welch V, Rutjes AW, Jüni P, Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2014;: CD003115" data-value-piped="da Costa BR, Nüesch E, Kasteler R, Husni E, Welch V, Rutjes AW, Jüni P|Oral or transdermal opioids for osteoarthritis of the knee or hip.|Cochrane Database Syst Rev|2014||CD003115|25229835" data-url="reference-link" data-pubmedid="25229835" title="da Costa BR, Nüesch E, Kasteler R, Husni E, Welch V, Rutjes AW, Jüni P, Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2014;: CD003115"><sup>4</sup></a> </li> </ul> </li> <li>Nedtrapning <ul> <li>Hvis patienterne bliver smertefrie, bør der gøres seponeringsforsøg</li> <li>Evt. kan man overgå til behandling ved behov, eller intermitterende behandling</li> </ul> </li> <li>Det er vigtigt at diskutere bivirkninger med patienterne</li> <li>Ingen medikamentel behandling har dokumenteret effekt på selve bruskødelæggelsen, hverken i positiv eller negativ retning</li> </ul> <h4>Medikamenter</h4> <ul> <li>Svage analgetika <ul> <li>Anbefales som førstevalg i perioder med smerter</li> <li>Fx [DliActiveSubstance;6381;paracetamol]: 1 g x 4 i 1 - 4 uger<a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD19201242559&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H19201243340&us=sitecore%5Canvi&mo&pe=0&fbd=1" data-type="journal-reference" data-value="Altman RD, Zinsenheim JR, Temple AR, Schweinle JE, Three-month efficacy and safety of acetominophen extended release for osteoarthritis pain of the hip or knee: a randomized, double-blind, placebo-controlled trial. Osteoarthritis Cartilage 2007;15: 454-61" data-value-piped="Altman RD, Zinsenheim JR, Temple AR, Schweinle JE|Three-month efficacy and safety of acetominophen extended release for osteoarthritis pain of the hip or knee: a randomized, double-blind, placebo-controlled trial|Osteoarthritis Cartilage|2007|15|454-61" data-url="reference-link" title="Altman RD, Zinsenheim JR, Temple AR, Schweinle JE, Three-month efficacy and safety of acetominophen extended release for osteoarthritis pain of the hip or knee: a randomized, double-blind, placebo-controlled trial. Osteoarthritis Cartilage 2007;15: 454-61"><sup>5</sup></a><sup>,</sup><a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD19201242559&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H19201243340&us=sitecore%5Canvi&mo&pe=0&fbd=1" data-type="other-reference" data-value="Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev, issue 1, 2006." data-url="http://www.ncbi.nlm.nih.gov/pubmed/16437479" title="Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev, issue 1, 2006."><sup>6</sup></a></li> </ul> </li> <li><a href="http://pro.medicin.dk/Laegemiddelgrupper/Grupper/213010">NSAID</a> <ul> <li>Kan være nyttige som supplement i korte perioder med mange smerter<a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD19201242559&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H19201243340&us=sitecore%5Canvi&mo&pe=0&fbd=1" data-type="other-reference" data-value="Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev, issue 1, 2006." data-url="http://www.ncbi.nlm.nih.gov/pubmed/16437479" title="Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev, issue 1, 2006."><sup>6</sup></a></li> <li>NSAID kan gives som tablet eller appliceres lokalt.</li> <li>NSAID kan forårsage mavesår og maveblødning. For at undgå dette kan NSAID behandling kombineres med protonpumpehæmmer</li> <li>NSAID synes at kunne give hjerte-kar bivirkninger specielt ved patienter med hjerte- og karlidelser</li> <li>Behandling med NSAID bør gives med mindst mulige dosis og i kortest mulige periode</li> </ul> </li> <li>Andre medikamenter: <ul> <li>Glukosamin har ingen effekt <a rel="noopener noreferrer" href="https://www.sst.dk/da/Udgivelser/2012/NKR-Knaeartrose" target="_blank">(NKR-knæartrose 2012 Sundhedsstyrelsen)</a><a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD19201242559&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H19201243340&us=sitecore%5Canvi&mo&pe=0&fbd=1" data-type="journal-reference" data-value="Runhaar J, Rozendaal RM, van Middelkoop M, Bijlsma HJW, Doherty M, Dziedzic KS, Lohmander LS, McAlindon T, Zhang W, Bierma Zeinstra S, Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank. Ann Rheum Dis 2017;76: 1862-1869" data-value-piped="Runhaar J, Rozendaal RM, van Middelkoop M, Bijlsma HJW, Doherty M, Dziedzic KS, Lohmander LS, McAlindon T, Zhang W, Bierma Zeinstra S|Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank.|Ann Rheum Dis|2017|76|1862-1869|28754801" data-url="reference-link" data-pubmedid="28754801" title="Runhaar J, Rozendaal RM, van Middelkoop M, Bijlsma HJW, Doherty M, Dziedzic KS, Lohmander LS, McAlindon T, Zhang W, Bierma Zeinstra S, Subgroup analyses of the effectiveness of oral glucosamine for knee and hip osteoarthritis: a systematic review and individual patient data meta-analysis from the OA trial bank. Ann Rheum Dis 2017;76: 1862-1869"><sup>7</sup></a></li> <li>Tramadol bør undgås</li> <li>Opiater bør undgås <a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD15369374474&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H15369374529&us=sitecore%5Csoko&mo&pe=0&fbd=1" data-type="journal-reference" data-value="da Costa BR, Nüesch E, Kasteler R, Husni E, Welch V, Rutjes AW, Jüni P, Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2014;: CD003115" data-value-piped="da Costa BR, Nüesch E, Kasteler R, Husni E, Welch V, Rutjes AW, Jüni P|Oral or transdermal opioids for osteoarthritis of the knee or hip.|Cochrane Database Syst Rev|2014||CD003115|25229835" data-url="reference-link" data-pubmedid="25229835" title="da Costa BR, Nüesch E, Kasteler R, Husni E, Welch V, Rutjes AW, Jüni P, Oral or transdermal opioids for osteoarthritis of the knee or hip. Cochrane Database Syst Rev 2014;: CD003115"><sup>4</sup></a></li> </ul> </li> </ul> <h3>Ikke kirurgisk behandling<a href="https://www.sst.dk/da/udgivelser/2021/NKR-Hofteartrose--ikke-kirurgisk-behandling-og-genoptraening-efter-THA" data-type="other-reference" data-value="NKR: Hofteartrose – ikke-kirurgisk behandling og genoptræning efter total hoftealloplastik" data-url="https://www.sst.dk/da/udgivelser/2021/NKR-Hofteartrose--ikke-kirurgisk-behandling-og-genoptraening-efter-THA" title="NKR: Hofteartrose – ikke-kirurgisk behandling og genoptræning efter total hoftealloplastik"><sup>8</sup></a><sup>,</sup><a href=" " data-type="journal-reference" data-value="Mechlenburg I, Reimer LU, Kjeldsen T, Frydendal T, Dalgas U, [Effect of training in the different stages of hip osteoarthritis]. Ugeskr Laeger 2021;183: " data-value-piped="Mechlenburg I, Reimer LU, Kjeldsen T, Frydendal T, Dalgas U|[Effect of training in the different stages of hip osteoarthritis].|Ugeskr Laeger|2021|183||34219643" data-url="reference-link" data-pubmedid="34219643" title="Mechlenburg I, Reimer LU, Kjeldsen T, Frydendal T, Dalgas U, [Effect of training in the different stages of hip osteoarthritis]. Ugeskr Laeger 2021;183: "><sup>9</sup></a></h3> <ul> <li>Træning anbefales som første trin i behandling af hofteartrose</li> <li>Træning har en symptomlindrende effekt hos personer med mild til moderat hofteartrose</li> <li>Ved svær hofteartrose kan træning præoperativt og kortvarigt postoperativ formentlig medvirke til forbedret smerte, funktionsevne og muskelstyrke</li> <li>Overvej at tilbyde patienter med hofteartrose neuromuskulær/funktionel træning i tillæg til vanlig behandling <ul> <li>Neuromuskulær træning: Fokus på bevægekvalitet og træning af sensomotorisk kontrol og funktionel stabilitet</li> <li>Funktionel træning: Dagligdagsfunktioner som for eksempel gang, trappegang og rejse/sætte sig fra en stol</li> </ul> </li> <li>Overvej at tilbyde patienter med hofteartrose superviseret styrketræning i tillæg til vanlig behandling <ul> <li>Superviseret styrketræning: Styrkeøvelser med ekstern modstand og med en belastning på mindst 60 % af maksimal belastning</li> </ul> </li> <li>Overvej at tilbyde patienter med hofteartrose manuel terapi i tillæg til vanlig behandling</li> <li>Det er god praksis at tilbyde vægttabsintervention til overvægtige patienter med hofteartrose i tillæg til vanlig behandling</li> <li>Overvej at tilbyde kombineret patientuddannelse og træning i tillæg til vanlig behandling til patienter med hofteartrose</li> <li>Se <a href="~/link.aspx?_id=2921EFECD0C4445CAF903F807C70FB52&_z=z">film med øvelser for hofte</a> </li> </ul> <h3>Akupunktur</h3> <ul> <li>Har formentlig ingen eller meget lille effekt<a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD19201242559&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H19201243340&us=sitecore%5Canvi&mo&pe=0&fbd=1" data-type="journal-reference" data-value="Manheimer E, Cheng K, Wieland LS, Shen X, Lao L, Guo M, Berman BM, Acupuncture for hip osteoarthritis. Cochrane Database Syst Rev 2018;5: CD013010" data-value-piped="Manheimer E, Cheng K, Wieland LS, Shen X, Lao L, Guo M, Berman BM|Acupuncture for hip osteoarthritis.|Cochrane Database Syst Rev|2018|5|CD013010|29729027" data-url="reference-link" data-pubmedid="29729027" title="Manheimer E, Cheng K, Wieland LS, Shen X, Lao L, Guo M, Berman BM, Acupuncture for hip osteoarthritis. Cochrane Database Syst Rev 2018;5: CD013010"><sup>10</sup></a></li> </ul> <h3>Kirurgi</h3> <h4>Protesekirurgi</h4> <ul> <li>Optimalt tidspunkt for kirurgi er ikke afklaret<a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD19201242559&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H19201243340&us=sitecore%5Canvi&mo&pe=0&fbd=1" data-type="journal-reference" data-value="Lane NE, Osteoarthritis of the hip. N Engl J Med 2007;357: 1413-21" data-value-piped="Lane NE|Osteoarthritis of the hip|N Engl J Med|2007|357|1413-21" data-url="reference-link" title="Lane NE, Osteoarthritis of the hip. N Engl J Med 2007;357: 1413-21"><sup>1</sup></a>, effekten er muligvis bedre ved operation tidligt i forløbet inden der tabes for meget muskelmasse og funktion<a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD19201242559&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H19201243340&us=sitecore%5Canvi&mo&pe=0&fbd=1" data-type="journal-reference" data-value="Fortin PR, Penrod JR, Clarke AE, et al, Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. Arthritis Rheum 2002;46: 3327-30" data-value-piped="Fortin PR, Penrod JR, Clarke AE, et al|Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee|Arthritis Rheum|2002|46|3327-30" data-url="reference-link" title="Fortin PR, Penrod JR, Clarke AE, et al, Timing of total joint replacement affects clinical outcomes among patients with osteoarthritis of the hip or knee. Arthritis Rheum 2002;46: 3327-30"><sup>11</sup></a></li> <li>Størst effekt ses dog hos patienter med de sværeste grader af artrose</li> <li>Stadige forbedringer <ul> <li>Bedre materialer og bedre design har ført til øget bevægelighed, forstærket stabilitet og nedsat slitage</li> <li>Hurtig mobilisering efter kirurgi </li> </ul> </li> <li>Andre typer kirurgi? <ul> <li>I sjældne tilfælde kan andre former for kirurgi være aktuelle</li> <li>Dette kan være korrigerende osteotomier på bækken eller femursiden. Disse indgreb udføres oftest hos yngre patienter med hoftedysplasi med minimale eller ingen røntgenologiske tegn på artrose. Hos patienter over 45 år med symptomatisk hoftedysplasi og ingen tegn på artrose og ingen overvægt kan overvejes osteotomi på bækken<a href="https://www.ortopaedi.dk/wp-content/uploads/2023/11/2023-KKR-Behandling-af-hoftedysplasi-%E2%80%93-PAO-for-patienter-over-45-aar-inkl-hoeringssvar_uploaded.pdf" data-type="other-reference" data-value="Kort klinisk retningslinie fra Dansk Ortopædkirurgisk Selskab 2023 omkring Periacetabularosteomi (PAO) for patienter over 45 år med symptomatisk hoftedysplasi. " data-url="https://www.ortopaedi.dk/wp-content/uploads/2023/11/2023-KKR-Behandling-af-hoftedysplasi-%E2%80%93-PAO-for-patienter-over-45-aar-inkl-hoeringssvar_uploaded.pdf" title="Kort klinisk retningslinie fra Dansk Ortopædkirurgisk Selskab 2023 omkring Periacetabularosteomi (PAO) for patienter over 45 år med symptomatisk hoftedysplasi. "><sup>12</sup></a></li> </ul> </li> </ul> <h4>Langtidseffekt</h4> <ul> <li>Positive effekter <ul> <li>Overlevelsen af hofteproteser (før revision til ny protese eller fjernelse fra leddet) er over 90 % efter 10 år, og cirka 80 % af patienterne er tilfredse</li> </ul> </li> <li>Negative effekter <ul> <li>For opererede patienter - løsning af protese, infektion, luksation, fraktur omkring protese</li> <li>Ingen proteser sidder biologisk fastvokset, idet der kun opstår en mekanisk forbindelse mellem protese/cement/knogle pga. ujævnheder</li> </ul> <ul> <li>Der kan derfor opstå mikrobevægelser i forbindelseszonerne ved brug af ekstremiteten. Disse bevægelser medfører dog ikke smerter, og protesen betragtes som fast forankret</li> <li>De fleste proteser er imidlertid klinisk løse efter 15-20 år</li> <li>Det er heller ikke usædvanligt, at proteser løsner sig tidligere</li> <li>Man må regne med en gennemsnitlig revisionshyppighed på 2,5 % efter fem år<a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD15369374474&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H15369374529&us=sitecore%5Csoko&mo&pe=0&fbd=1" data-type="journal-reference" data-value="Espehaug B, Havelin LI, Engesæter LB, Vollset SE, Langeland N, Early revision among 12,179 hip prostheses: a comparison of 10 different brands reported to the Norwegian Arthroplasty Register, 1987 - 1993. Acta Orthop Scand 1995;66: 487 - 93" data-value-piped="Espehaug B, Havelin LI, Engesæter LB, Vollset SE, Langeland N|Early revision among 12,179 hip prostheses: a comparison of 10 different brands reported to the Norwegian Arthroplasty Register, 1987 - 1993|Acta Orthop Scand|1995|66|487 - 93" data-url="reference-link" title="Espehaug B, Havelin LI, Engesæter LB, Vollset SE, Langeland N, Early revision among 12,179 hip prostheses: a comparison of 10 different brands reported to the Norwegian Arthroplasty Register, 1987 - 1993. Acta Orthop Scand 1995;66: 487 - 93"><sup>13</sup></a></li> <li>Ved recidiverende hofteluksationer kan der indsættes specialprotese (constrained liner)</li> </ul> </li> </ul> <h4>Rehabilitering</h4> <ul> <li>Patienten bør efter operationen følge en rehabiliteringsplan - varigheden afhænger af individuelle behov</li> <li>Genoptræningen bedrer patientens funktion</li> <li>Maksimal reduktion af smerter og bedring i funktion efter total hofteplastik kan tage op til 12 måneder</li> <li>Den nationale kliniske retningslinje for hofteartrose konkluderer at man<a href="https://www.sst.dk/da/udgivelser/2021/NKR-Hofteartrose--ikke-kirurgisk-behandling-og-genoptraening-efter-THA" data-type="other-reference" data-value="NKR: Hofteartrose – ikke-kirurgisk behandling og genoptræning efter total hoftealloplastik" data-url="https://www.sst.dk/da/udgivelser/2021/NKR-Hofteartrose--ikke-kirurgisk-behandling-og-genoptraening-efter-THA" title="NKR: Hofteartrose – ikke-kirurgisk behandling og genoptræning efter total hoftealloplastik"><sup>8</sup></a>: <ul> <li>Kun bør anvende superviseret genoptræning efter nøje overvejelse, da den gavnlige effekt af supervision er usikker</li> <li>Kun bør anvende superviseret styrketræning i tillæg til vanlig behandling efter nøje overvejelse, da der ikke er fundet en klinisk relevant forskel imellem effekten af superviseret styrketræning og vanlig behandling</li> <li>Overveje at anbefale patienter, der er opereret, at overholde en grad af bevægerestriktioner i en begrænset tidsperiode postoperativt</li> </ul> </li> </ul> <h3>Forebyggende behandling</h3> <ul> <li>Præoperativt <ul> <li>Vægtreduktion og optræning af muskulatur har gunstig effekt på udfaldet</li> <li>Rygeophør reducerer hyppigheden af komplikationer<a href="EditorPage.aspx?da=core&id=%7B459F747F-3A1F-4339-B887-DA7BB7A3FC2F%7D&ed=FIELD19201242559&vs&la=da&fld=%7B850D32D3-55A1-49E4-9CDF-F0C88D91563C%7D&so=%2Fsitecore%2Fsystem%2FSettings%2FHtml%20Editor%20Profiles%2FRich%20Text%20LHPH&di=0&hdl=H19201243340&us=sitecore%5Canvi&mo&pe=0&fbd=1" data-type="journal-reference" data-value="Møller AM, Villebro N, Pedersen T, et al, Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet 2002;359: 114-7" data-value-piped="Møller AM, Villebro N, Pedersen T, et al|Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial|Lancet|2002|359|114-7" data-url="reference-link" title="Møller AM, Villebro N, Pedersen T, et al, Effect of preoperative smoking intervention on postoperative complications: a randomised clinical trial. Lancet 2002;359: 114-7"><sup>14</sup></a></li> </ul> </li> <li>Tidlig postoperativ mobilisering <ul> <li>Hindrer komplikationer som fx pneumoni og dyb venetrombose</li> </ul> </li> </ul> <h2>Henvisning</h2> <h3>Til ortopæd</h3> <ul> <li>Ved manglende effekt af initial behandling (træning, vægtreduktion ved behov, medicinsk smertebehandling) </li> <li>Udtalte nattesmerter</li> <li>Kontrakturer</li> <li>Problemer med at fungere i dagliglivet på grund af hoftegener</li> <li>Artrose hos unge patienter</li> <li>I henvisningen angives de behandlingstiltag (svage analgetika, træning), som har været iværksat forud for henvisning til ortopædkirurg</li> </ul> <h2>Opfølgning</h2> <h3>Plan</h3> <ul> <li>Patienten følges op efter behov</li> </ul> <h2>Sygdomsforløb, komplikationer og prognose</h2> <h3>Sygdomsforløb</h3> <ul> <li>Normalt sker der en gradvis progression af tilstanden, men mange fungerer godt med konservative tiltag i lange perioder</li> <li>Artrose har ofte et fluktuerende forløb, af og til med spontan forbedring af både symptomer og ledstruktur </li> <li>Hos en del bliver de smertefri perioder efterhånden kortere med en tendens til, at smerterne varer ved, også under hvile og evt. med smerter om natten</li> </ul> <h3>Komplikationer</h3> <ul> <li>Atrofi og immobilisering</li> </ul> <h3>Prognose</h3> <ul> <li>Mange har tilfredsstillende effekt af konservative tiltag</li> <li>Hos patienter som opereres, vil de fleste blive betydeligt bedre. De bedste resultater opnås blandt dem med mest udtalte gener før operationen</li> <li>Data fra norsk nationalt register for ledproteser viser, at 10 % af proteserne bliver revideret i løbet af 10 år pga. løsning</li> <li>Baseret på data fra skandinaviske registre synes det som om, at 80 % af patienterne har smertefri og velfungerende hofte 10 år efter en primær operation med total protese</li> </ul> <h2>Baggrundsoplysninger</h2> <h3>Definition</h3> <ul> <li>Degenerative forandringer i hofteleddet </li> <li>Artrose er en samlebetegnelse for ledsygdomme, som karakteriseres af svigtende ledfunktion med varierende ødelæggelse af ledbrusk og påvirkning af lednær knogle<a href=" " data-type="journal-reference" data-value="Dieppe PA, Lohmander LS, Pathogenesis and management of pain in osteoarthritis. Lancet 2005;365: 965-73" data-value-piped="Dieppe PA, Lohmander LS|Pathogenesis and management of pain in osteoarthritis|Lancet|2005|365|965-73" data-url="reference-link" title="Dieppe PA, Lohmander LS, Pathogenesis and management of pain in osteoarthritis. Lancet 2005;365: 965-73"><sup>15</sup></a><sup>,</sup><a href=" " data-type="journal-reference" data-value="Lane NE, Osteoarthritis of the hip. N Engl J Med 2007;357: 1413-21" data-value-piped="Lane NE|Osteoarthritis of the hip|N Engl J Med|2007|357|1413-21" data-url="reference-link" title="Lane NE, Osteoarthritis of the hip. N Engl J Med 2007;357: 1413-21"><sup>1</sup></a> </li> <li>Ved røntgenundersøgelse af et led med artrose ses forandringer som reduceret ledspalte, subkondral sklerose, osteofytter og cystedannelse</li> <li>Der er i mange tilfælde diskrepans mellem røntgenfund og symptomer, specielt graden af smerte<a href=" " data-type="journal-reference" data-value="Lane NE, Osteoarthritis of the hip. N Engl J Med 2007;357: 1413-21" data-value-piped="Lane NE|Osteoarthritis of the hip|N Engl J Med|2007|357|1413-21" data-url="reference-link" title="Lane NE, Osteoarthritis of the hip. N Engl J Med 2007;357: 1413-21"><sup>1</sup></a></li> </ul> <h3>Forekomst</h3> <ul> <li>Artrose forekommer hyppigst i hofteleddet</li> <li>Prævalens <ul> <li>Symptomgivende primær artrose angives i den kaukasiske befolkning over 55 år at være ca. 1,6 %, og den stiger stærkt med alderen</li> <li>90 % af patienter over 65 år, som klager over hoftesmerter, har artrose i hofteleddet</li> </ul> </li> <li>Hofteoperationer <ul> <li>Årlig indsættes der ca. 12.000 hofteproteser i Danmark<a href="https://danskhoftealloplastikregister.dk/wp-content/uploads/2016/04/DHR-%C3%A5rsrapport-2018_til-offentligg%C3%B8relse.pdf" data-type="other-reference" data-value="Årsrapport 2018: Dansk Hoftealloplastik Register" data-url="https://danskhoftealloplastikregister.dk/wp-content/uploads/2016/04/DHR-%C3%A5rsrapport-2018_til-offentligg%C3%B8relse.pdf" title="Årsrapport 2018: Dansk Hoftealloplastik Register"><sup>16</sup></a> (2018), og af disse er ca. 10 % re-operationer</li> </ul> </li> </ul> <h3>Ætiologi og patogenese</h3> <ul> <li>Artroseforandringer kommer som resultat af længere tids slitage mod brusken i ledfladerne<a href=" " data-type="journal-reference" data-value="Lane NE, Osteoarthritis of the hip. N Engl J Med 2007;357: 1413-21" data-value-piped="Lane NE|Osteoarthritis of the hip|N Engl J Med|2007|357|1413-21" data-url="reference-link" title="Lane NE, Osteoarthritis of the hip. N Engl J Med 2007;357: 1413-21"><sup>1</sup></a> </li> <li>Bruskskaden efterfølges af kondensering af den subkondrale knogle, dannelse af knogleudbygning (osteofytter) og mild til moderat synovial inflammation </li> <li>Det er påvist, at synovia udskiller proteintransmittere, som stimulerer kondrocytterne til produktion af et proteindegraderende enzym. Synovit-tilstande står derfor centralt i artrose-patogenesen </li> <li>Arvelige faktorer kan have betydning for udvikling af sygdommen<a href=" " data-type="journal-reference" data-value="Lanyon P, Muir K, Doherty S, Doherty M, Assessment of a genetic contribution to osteoarthritis of the hip: sibling study. BMJ 2000;321: 1179-83" data-value-piped="Lanyon P, Muir K, Doherty S, Doherty M|Assessment of a genetic contribution to osteoarthritis of the hip: sibling study.|BMJ|2000|321|1179-83|11073507" data-url="reference-link" data-pubmedid="11073507" title="Lanyon P, Muir K, Doherty S, Doherty M, Assessment of a genetic contribution to osteoarthritis of the hip: sibling study. BMJ 2000;321: 1179-83"><sup>17</sup></a> </li> <li>Det skelnes mellem primær (idiopatisk) og sekundær hofteledsartrose</li> </ul> <h3>Disponerende faktorer</h3> <ul> <li>Alder </li> <li>Overvægt </li> <li>Ledfladeinkongruens som følge af fraktur, <a href="~/link.aspx?_id=E666CD5F2753479CA957375F16C73E2D&_z=z">mb. Calvé-Legg-Perthes</a>, epifysiolyse</li> <li>Ledinflammation fx<a href="~/link.aspx?_id=939AB6BE2EA74C2890648DEA4AF5E6C6&_z=z"> reumatoid artrit</a>, <a href="~/link.aspx?_id=E82C4BA484D14374B5625D94EFEB9925&_z=z">psoriasis artrit</a>, septisk artrit, <a href="~/link.aspx?_id=2B3022F9A5604E188E7E032EDBB010FC&_z=z">Mb Bechterew</a></li> <li>Deformiteter i børne- og ungdomsalderen herunder<a href="~/link.aspx?_id=579307F3581C4832B59CBED7D9A3999B&_z=z"> hofteledsdysplasi</a> og coxa vara </li> <li>Metaboliske lidelser for eksempel kondrokalcinose </li> <li><a href="~/link.aspx?_id=6D1FE04BD5C84ABB9860EA1204019A98&_z=z">Hæmofili </a>med ledblødninger </li> <li>Neuropati - Charcot-led </li> <li>Avaskulær caput-nekrose </li> <li>Erhverv som er fysisk krævende, fx hvor der stås meget op, løft eller flytning af tunge genstande<a href=" " data-type="journal-reference" data-value="Lievense AM, Bierma-Zeinstra SA, Verhagen AP, Verhaar JAS, Koes BW, Influence of work on the development of osteoarthritis of the hip: a systematic review. J Rheumatol 2001;28: 2520-8" data-value-piped="Lievense AM, Bierma-Zeinstra SA, Verhagen AP, Verhaar JAS, Koes BW|Influence of work on the development of osteoarthritis of the hip: a systematic review|J Rheumatol|2001|28|2520-8" data-url="reference-link" title="Lievense AM, Bierma-Zeinstra SA, Verhagen AP, Verhaar JAS, Koes BW, Influence of work on the development of osteoarthritis of the hip: a systematic review. J Rheumatol 2001;28: 2520-8"><sup>18</sup></a> </li> <li>Deltagelse i vægtbærende idræt (løb på eliteniveau)<a href=" " data-type="journal-reference" data-value="Lievense AM, Bierma-Zeinstra SA, Verhagen AP, Bernsen RM, Verhaar JAS, Koes BW, Influence of sporting activities on the development of osteoarthritis of the hip: a systematic review. Arthritis Rheum 2003;49: 228-36" data-value-piped="Lievense AM, Bierma-Zeinstra SA, Verhagen AP, Bernsen RM, Verhaar JAS, Koes BW|Influence of sporting activities on the development of osteoarthritis of the hip: a systematic review|Arthritis Rheum|2003|49|228-36" data-url="reference-link" title="Lievense AM, Bierma-Zeinstra SA, Verhagen AP, Bernsen RM, Verhaar JAS, Koes BW, Influence of sporting activities on the development of osteoarthritis of the hip: a systematic review. Arthritis Rheum 2003;49: 228-36"><sup>19</sup></a></li> </ul> <h3>ICPC-2</h3> <p>[ICPC]</p> <h3>ICD-10/SKS-koder</h3> <p>[ICD10]</p> <h2>Patientinformation</h2> <h3>Hvad du bør informere patienten om</h3> <ul> <li>At dette er en ufarlig tilstand, som i perioder kan give varierende grad af gener</li> <li>Vigtigheden af vægtreduktion og tiltag beskrevet under egenbehandling</li> </ul> <h3>Hvad findes af skriftlig patientinformation</h3> <ul> <li><a href="~/link.aspx?_id=17E70606FA664620A32D16A591713926&_z=z">Information om hofteartrose</a></li> <li><a href="~/link.aspx?_id=D7B1EEBC5AEF46F28E7EDE14914A7DF1&_z=z">Total hofteprotese</a></li> <li><a href="~/link.aspx?_id=4883B68F2D274554AA64B27B73795C0D&_z=z">Om proteseinfektion</a></li> <li><a href="~/link.aspx?_id=7733A1DE69624B12AFCB54770113A729&_z=z">Råd til en lettere hverdag med leddegigt</a></li> <li><a href="https://hmi-basen.dk/news.asp?newsid=12913&x_newstype=39">Hjælpemiddelbasen, Gigt</a></li> <li>Podcast fra Gigtforeningen om slidgigt i hoften<a href="https://www.gigtforeningen.dk/viden-om-gigt/diagnoser/slidgigt/" data-type="other-reference" data-value="Podcast fra Gigtforeningen om slidgigt i hoften" data-url="https://www.gigtforeningen.dk/viden-om-gigt/diagnoser/slidgigt/ " title="Podcast fra Gigtforeningen om slidgigt i hoften"><sup>20</sup></a></li> </ul> <h3>Træningsfilm for hoften</h3> <ul> <li><a href="~/link.aspx?_id=818B397C2AB842C099A97B8062EFD8E3&_z=z">Øvelsesprogram, 3 øvelser</a><br> <br> <a href="~/link.aspx?_id=2921EFECD0C4445CAF903F807C70FB52&_z=z"><img alt="Video af øvelser til hoften. " src="9C5B771B780A41A19989427EB606036A-135-84" title="Klik for at se introduktionsvideoen" style="height: 84px; width: 135px;" height="84" width="135"></a><br> <br> </li> <li><a href="~/link.aspx?_id=AFFE794173B84353A6F24E26DBA2D429&_z=z">Øvelsesprogram, 3 øvelser med arabisk tale - فيديوهات تمارين رياضية باللغة العربية</a><br> <br> <a href="~/link.aspx?_id=4B5988BBA14F4FB684F38176054DA4AF&_z=z"><img alt="Video af øvelser til hoften på arabisk." src="737E9F0FEE87480FBBB49E2FF87F2196-135-84" title="Klik for at se introduktionsvideoen" style="height: 84px; width: 135px;" height="84" width="135"></a></li> </ul> <h3>Animationer</h3> <ul> <li><a href="~/link.aspx?_id=DB5D9AA20A6F4A0187E7D87373AA2B5E&_z=z">Slidgigt (artrose)</a></li> <li><a href="~/link.aspx?_id=00C45D64C94B4773AD296565E53BED4B&_z=z">Slidgigt i hoften</a></li> <li><a href="~/link.aspx?_id=C274D735931F4CA880D0AFD350B1DF93&_z=z">Indsættelse af kunstigt hofteled</a></li> </ul> <h2>Link til vejledninger</h2> <ul> <li>Forløbsbeskrivelser og pakkeforløb [ICPC]</li> </ul> <h2>Illustrationer</h2> <h3>Billeder</h3> <ul> <li> <a href="~/link.aspx?_id=DFB62F87F5204AEBB14C954C3964F099&_z=z">Coxartrose, rtg., alvorlig</a> </li> <li> <a href="~/link.aspx?_id=28FE9662F0AC451998A23BBF3E695A4C&_z=z">Bilateral coxartrose, moderat og svær grad</a> </li> <li> <a href="~/link.aspx?_id=C3B4DD559BA6478997B810B97CEB1609&_z=z">Totalprotese i hofte, rtg.</a> </li> <li> <a href="~/link.aspx?_id=6AF0F30758CB417FB2975C0148E34C76&_z=z">Normal hofte, rtg.</a> </li> </ul> <h3>Plancher eller tegninger</h3> <ul> <li> <a href="~/link.aspx?_id=D151452AD9C44077B47216B963126570&_z=z">Normalt hofteled, tegning</a> </li> <li> <a href="~/link.aspx?_id=0FE1CB93DC2940C5BED7CBEB1E6BCB9D&_z=z">Oversigt lår/hofte/bækken, tegning</a></li> </ul>]]></HtmlField> <HtmlField Name="Resume"><![CDATA[<h2>Resumé</h2> <h3>Diagnose</h3> <ul> <li>Betydelige aktivitetsrelaterede hoftesmerter</li> <li>Nedsat bevægelighed af hofteled</li> <li>Radiologiske tegn på artrose</li> </ul> <h3>Behandling</h3> <ul> <li>Primært symptomlindrende: træning, vægttab, medicinsk smertebehandling</li> <li>Total hofteprotese ved manglende effekt af ovenstående</li> </ul> <h3>Henvisning</h3> <ul> <li>Når træning (og evt. vægttab) har været forsøgt uden effekt</li> <li>Når medicinsk smertebehandling ikke er tilstrækkelig</li> </ul>]]></HtmlField> <LinkListField Name="Spot2"> <LinkField linktype="internal">{99A85AFD-2F7A-4B5D-A1C9-C2701D5E7D30}</LinkField> </LinkListField> <TextField Name="DoctorsHandbookID">2750</TextField> <TextField Name="PageTitle">Artrose, hofte</TextField> <TextField Name="NavigationTitle">Artrose, hofte</TextField> <CheckBoxField Name="ShowInMenu">true</CheckBoxField> <CheckBoxField Name="ShowInContentField">true</CheckBoxField> <DateTimeField Name="RevisedDate">2024-09-23T10:36:00</DateTimeField> <LinkListField Name="Authors"> <LinkField linktype="internal">{CE2BA99D-50C9-4893-9B3A-504CFF36BD80}</LinkField> <LinkField linktype="internal">{ED7CEC94-3F7A-4FB5-BBB0-A3681BCFC481}</LinkField> </LinkListField> <LinkListField Name="Organization"> <LinkField linktype="internal">{CF77E8B9-9937-42B2-85DF-76B0F4E401F0}</LinkField> </LinkListField> <TextField Name="ICD10">M16</TextField> <TextField Name="ICPC2">L89</TextField> <LinkListField Name="SearchAreaID"> <LinkField linktype="internal">2</LinkField> </LinkListField> <TextField Name="Description">Artrose er en samlebetegnelse for ledsygdomme, som karakteriseres af svigtende ledfunktion med varierende ødelæggelse af ledbrusk og påvirkning af lednær knogle.</TextField> <LinkListField Name="LHPHEditor"> <LinkField linktype="internal">{C70DFB71-BE40-455A-BD6B-5AFF199797D9}</LinkField> </LinkListField> <TextField Name="__Updated by">sitecore\long</TextField> <TextField Name="MetaKeywords">artrose, artrose hofte, coxarthrosis, hhs, hip harris score, hofteartrose, hofteledsartrose, osteoartrose, osteoartritis, slidgigt, Artrose, hofteartrose, hofteslidgigt, slidgigt i hofte</TextField> <LinkListField Name="InformationCategory"> <LinkField linktype="internal">IC_13</LinkField> </LinkListField> <LinkListField Name="InformationType"> <LinkField linktype="internal">7</LinkField> </LinkListField> <LinkListField Name="SearchTargetGroup"> <LinkField linktype="internal">2</LinkField> </LinkListField> </Content> <Medias> <Media Id="9C5B771B780A41A19989427EB606036A-135-84" Name="hofteøvelser thumbnail med playknap" MimeType="image/jpeg" Extension="jpg" Width="135" Height="84"><![CDATA[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]]></Media> <Media Id="737E9F0FEE87480FBBB49E2FF87F2196-135-84" Name="laenderygoevelser-arabisk-play" MimeType="image/jpeg" Extension="jpg" Width="135" Height="84"><![CDATA[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]]></Media> </Medias> </Item> </Provider>
89.368 characters